ARTICLE | Company News
EMA to review ridaforolimus
August 18, 2011 11:43 PM UTC
EMA accepted for review an MAA from Merck & Co. Inc. (NYSE:MRK) for ridaforolimus to treat metastatic sarcomas. The acceptance triggers a $25 million milestone payment to Ariad Pharmaceuticals Inc. (N...